Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

2 Apr 2010

Abstract excerpt

Statin inhibitors, used to control hypercholesterolemia, trigger apoptosis of hematologic tumor cells and therefore have immediate potential as anticancer agents. Evaluations of statins in acute myelogenous leukemia and multiple myeloma have shown that statin efficacy is mixed, with only a subset of tumor cells being highly responsive. Our goal was to distinguish molecular features of statin-sensitive and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Cancer Mechanisms and Therapy
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20360469
DOI: 10.1182/blood-2009-07-230508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myelomaPMID 20360469Read ↗

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.Semantic proximity Read ↗

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell deathSemantic proximity Read ↗

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RASSemantic proximity Read ↗

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myelomaSemantic proximity Read ↗

Mevalonate Pathway and Human Cancers.Semantic proximity Read ↗

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.Semantic proximity Read ↗

Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinomaSemantic proximity Read ↗

High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancerSemantic proximity Read ↗

Lipophilic statins antagonistically alter the major epithelial‐to‐mesenchymal transition signaling pathways in breast cancer stem–like cells via inhibition of the mevalonate pathwaySemantic proximity Read ↗

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.Semantic proximity Read ↗

The role of statins as therapeutic agents in cancerSemantic proximity Read ↗

Statins are potential anticancerous agents (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.